J. Zinckgraf

发表

Antibody responses to a mucosally delivered HIV-1 gp120-derived C4/V3 peptide.

L. Silbart, J. Winchell, J. Zinckgraf, 2000, Journal of reproductive immunology.

Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers.

E. von Hofe, Minzhen Xu, J. Zinckgraf, 2009, Vaccine.

Cloning and Characterization of a Hybridoma Secreting a 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-Specific Monoclonal Antibody and Recombinant F(ab)

L. Silbart, H. Wanczyk, M. Lynes, 2013, Toxins.

Effect of passive antibodies derived from rotavirus-like particles on neonatal calf diarrhea caused by rotavirus in an oral challenge model

G. Duhamel, D. Nydam, J. Crabb, 2021, Journal of Dairy Science.

Non-toxic Pseudomonas aeruginosa exotoxin A expressing the FMDV VP1 G-H loop for mucosal vaccination of swine against foot and mouth disease virus.

L. Silbart, R. French, Sreerupa Challa, 2007, Vaccine.

Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.

J. Treanor, D. Powell, E. von Hofe, 2009, Vaccine.

Modulating gene expression using DNA vaccines with different 3'-UTRs influences antibody titer, seroconversion and cytokine profiles.

L. Silbart, J. Zinckgraf, 2003, Vaccine.

with Reduced Immunogenicity Rationally Engineered Therapeutic Proteins

A. Sette, B. Mothé, R. Chesnut, 2017 .

Rationally Engineered Therapeutic Proteins with Reduced Immunogenicity

John Sidney, Alessandro Sette, Scott Southwood, 2005, The Journal of Immunology.